Fifth Third Bancorp Buys 3,201 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Fifth Third Bancorp increased its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 769.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,617 shares of the specialty pharmaceutical company's stock after purchasing an additional 3,201 shares during the period. Fifth Third Bancorp's holdings in Jazz Pharmaceuticals were worth $449,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Focus Partners Wealth acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $551,000. Atria Investments Inc lifted its stake in Jazz Pharmaceuticals by 19.5% in the fourth quarter. Atria Investments Inc now owns 2,732 shares of the specialty pharmaceutical company's stock valued at $336,000 after buying an additional 445 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Jazz Pharmaceuticals by 15.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 615,517 shares of the specialty pharmaceutical company's stock worth $75,801,000 after purchasing an additional 83,807 shares during the period. CX Institutional acquired a new stake in shares of Jazz Pharmaceuticals during the first quarter worth about $4,316,000. Finally, Rhumbline Advisers raised its position in shares of Jazz Pharmaceuticals by 1.1% during the fourth quarter. Rhumbline Advisers now owns 167,560 shares of the specialty pharmaceutical company's stock worth $20,635,000 after purchasing an additional 1,755 shares during the period. 89.14% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Seamus Mulligan purchased 1,621 shares of Jazz Pharmaceuticals stock in a transaction on Monday, May 12th. The shares were purchased at an average price of $103.00 per share, for a total transaction of $166,963.00. Following the transaction, the director now owns 101,621 shares of the company's stock, valued at approximately $10,466,963. This represents a 1.62% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 500 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $107.90, for a total value of $53,950.00. Following the completion of the sale, the chief executive officer now owns 438,473 shares in the company, valued at $47,311,236.70. This trade represents a 0.11% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,000 shares of company stock worth $355,925 in the last 90 days. Insiders own 4.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on JAZZ shares. Piper Sandler reiterated an "overweight" rating and set a $147.00 price objective (down from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Needham & Company LLC reiterated a "buy" rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, June 11th. HC Wainwright increased their price objective on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a report on Monday, March 10th. Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and raised their price target for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. Finally, UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price target for the company from $145.00 to $179.00 in a research note on Friday, March 7th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $184.00.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ traded down $0.73 during midday trading on Friday, hitting $107.51. The company had a trading volume of 1,053,788 shares, compared to its average volume of 827,456. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $148.06. The firm has a 50-day moving average price of $108.14 and a 200-day moving average price of $120.06. The company has a current ratio of 3.38, a quick ratio of 2.97 and a debt-to-equity ratio of 1.28. The company has a market capitalization of $6.51 billion, a PE ratio of 14.33, a P/E/G ratio of 4.64 and a beta of 0.33.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The firm had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The company's revenue was down .5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.68 EPS. As a group, analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.